At the news
? NEUTRALIMPACT 3/10 SC 13G filed Nov 10, 2026 at 08:22 ET
State Street Corp disclosed a 4.8% passive stake in Iovance Biotherapeutics as of September 30, 2026, via a Schedule 13G filing. This is a routine update of its existing passive position, consistent with prior filings, and follows the company's strong Q3 earnings report.
- State Street Corp reported beneficial ownership of 21,695,003 shares of Iovance common stock as of September 30, 2026.
- The stake represents 4.8% of shares outstanding.
- The filing is a Schedule 13G, certifying passive investment intent with no control or influence purpose.
- State Street has filed multiple prior 13Gs for Iovance, indicating a continuing passive position.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access